Business
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC
Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute. Company CEO David Weinstein shared how the company is using its proprietary AI platform to scale therapeutic discovery and strengthen biodefense preparedness.
About this update from Lunai Bioworks Inc.
[{"type":"text","content":"SACRAMENTO, Calif., Feb. 13, 2026 /PRNewswire/ -- Lunai Bioworks (NASDAQ: LNAI), an AI-powered biotech and biodefense company, was featured on CNBC's Business Minute. Company CEO David Weinstein shared how the company is using its proprietary AI platform to scale therapeutic discovery and strengthen biodefense preparedness.","length":329,"tagName":"p"},{"type":"image","alt":"Lunai Bioworks Inc. (PRNewsfoto/Lunai Bioworks Inc.)","displaySize":"","headline":null,"caption":"Lunai Bioworks Inc. (PRNewsfoto/Lunai Bioworks Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":123,"url":"https://media.zenfs.com/en/prnewswire.com/e1394d131f94f2906bb3fbc63140be9f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PR3.Qv1zkg2N7mzYMfWyzw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/e1394d131f94f2906bb3fbc63140be9f","width":400,"height":123}},"href":"https://mma.prnewswire.com/media/2814530/Lunai_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are deploying AI to accelerate discovery in CNS disease and biodefense," said David Weinstein, Chief Executive Officer of Lunai Bioworks. "Our platform is built to scale precision biology, reduce development risk, and advance high-impact therapeutic programs more efficiently."","length":301,"tagName":"p"},{"type":"text","content":"During the national segment, Weinstein discussed how Lunai integrates multimodal biological datasets, advanced machine learning, and in vivo validation systems to rapidly identify novel targets, optimize drug candidates, and compress development timelines across complex neurological disorders and emerging chemical and biological threat countermeasures.","length":354,"tagName":"p"},{"type":"text","content":"The CNBC appearance underscores growing investor attention on scalable AI platforms transforming central nervous system therapeutics and national security–focused biodefense innovation. Highlights of the interview aired on Business Minute can be watched via the following link:","length":277,"tagName":"p"},{"type":"text","content":"https://www.linkedin.com/posts/lunai-bioworks_were-proud-to-share-that-our-client-lunai-activity-7427770187589877760-hp3X","length":121,"tagName":"p"},{"type":"text","content":"Lunai is actively advancing ...